Drug Profile
Research programme: influenza virus DNA vaccine - Advanced Influenza Technologies
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator University of Massachusetts Medical School
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (Injection)
- 11 Jul 2007 Preclinical development is ongoing
- 21 Jul 2006 Preclinical trials in Influenza virus infections in USA (Injection)